These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

349 related items for PubMed ID: 12551968

  • 1. Changes in the immunogenic properties of soluble gp140 human immunodeficiency virus envelope constructs upon partial deletion of the second hypervariable region.
    Srivastava IK, VanDorsten K, Vojtech L, Barnett SW, Stamatatos L.
    J Virol; 2003 Feb; 77(4):2310-20. PubMed ID: 12551968
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Immunization with HIV-1 SF162-derived Envelope gp140 proteins does not protect macaques from heterologous simian-human immunodeficiency virus SHIV89.6P infection.
    Xu R, Srivastava IK, Kuller L, Zarkikh I, Kraft Z, Fagrouch Z, Letvin NL, Heeney JL, Barnett SW, Stamatatos L.
    Virology; 2006 Jun 05; 349(2):276-89. PubMed ID: 16527321
    [Abstract] [Full Text] [Related]

  • 5. The first hypervariable region of the gp120 Env glycoprotein defines the neutralizing susceptibility of heterologous human immunodeficiency virus type 1 isolates to neutralizing antibodies elicited by the SF162gp140 immunogen.
    Ching LK, Vlachogiannis G, Bosch KA, Stamatatos L.
    J Virol; 2008 Jan 05; 82(2):949-56. PubMed ID: 18003732
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Alterations in the immunogenic properties of soluble trimeric human immunodeficiency virus type 1 envelope proteins induced by deletion or heterologous substitutions of the V1 loop.
    Ching L, Stamatatos L.
    J Virol; 2010 Oct 05; 84(19):9932-46. PubMed ID: 20660181
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Comparison of HIV Type 1 ADA gp120 monomers versus gp140 trimers as immunogens for the induction of neutralizing antibodies.
    Kim M, Qiao ZS, Montefiori DC, Haynes BF, Reinherz EL, Liao HX.
    AIDS Res Hum Retroviruses; 2005 Jan 05; 21(1):58-67. PubMed ID: 15665645
    [Abstract] [Full Text] [Related]

  • 11. Generation and structural analysis of soluble oligomeric gp140 envelope proteins derived from neutralization-resistant and neutralization-susceptible primary HIV type 1 isolates.
    Stamatatos L, Lim M, Cheng-Mayer C.
    AIDS Res Hum Retroviruses; 2000 Jul 01; 16(10):981-94. PubMed ID: 10890360
    [Abstract] [Full Text] [Related]

  • 12. Characterization of antibody responses elicited by human immunodeficiency virus type 1 primary isolate trimeric and monomeric envelope glycoproteins in selected adjuvants.
    Li Y, Svehla K, Mathy NL, Voss G, Mascola JR, Wyatt R.
    J Virol; 2006 Feb 01; 80(3):1414-26. PubMed ID: 16415019
    [Abstract] [Full Text] [Related]

  • 13. Purification, characterization, and immunogenicity of a soluble trimeric envelope protein containing a partial deletion of the V2 loop derived from SF162, an R5-tropic human immunodeficiency virus type 1 isolate.
    Srivastava IK, Stamatatos L, Kan E, Vajdy M, Lian Y, Hilt S, Martin L, Vita C, Zhu P, Roux KH, Vojtech L, C Montefiori D, Donnelly J, Ulmer JB, Barnett SW.
    J Virol; 2003 Oct 01; 77(20):11244-59. PubMed ID: 14512572
    [Abstract] [Full Text] [Related]

  • 14. Immunogenicity and ability of variable loop-deleted human immunodeficiency virus type 1 envelope glycoproteins to elicit neutralizing antibodies.
    Kim YB, Han DP, Cao C, Cho MW.
    Virology; 2003 Jan 05; 305(1):124-37. PubMed ID: 12504547
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Immunogenicity of DNA vaccines expressing human immunodeficiency virus type 1 envelope glycoprotein with and without deletions in the V1/2 and V3 regions.
    Lu S, Wyatt R, Richmond JF, Mustafa F, Wang S, Weng J, Montefiori DC, Sodroski J, Robinson HL.
    AIDS Res Hum Retroviruses; 1998 Jan 20; 14(2):151-5. PubMed ID: 9462925
    [Abstract] [Full Text] [Related]

  • 18. A comparative immunogenicity study in rabbits of disulfide-stabilized, proteolytically cleaved, soluble trimeric human immunodeficiency virus type 1 gp140, trimeric cleavage-defective gp140 and monomeric gp120.
    Beddows S, Franti M, Dey AK, Kirschner M, Iyer SP, Fisch DC, Ketas T, Yuste E, Desrosiers RC, Klasse PJ, Maddon PJ, Olson WC, Moore JP.
    Virology; 2007 Apr 10; 360(2):329-40. PubMed ID: 17126869
    [Abstract] [Full Text] [Related]

  • 19. Isolation and characterization of monoclonal antibodies elicited by trimeric HIV-1 Env gp140 protein immunogens.
    Derby NR, Gray S, Wayner E, Campogan D, Vlahogiannis G, Kraft Z, Barnett SW, Srivastava IK, Stamatatos L.
    Virology; 2007 Sep 30; 366(2):433-45. PubMed ID: 17560621
    [Abstract] [Full Text] [Related]

  • 20. Neutralizing antibodies from the sera of human immunodeficiency virus type 1-infected individuals bind to monomeric gp120 and oligomeric gp140.
    Stamatos NM, Mascola JR, Kalyanaraman VS, Louder MK, Frampton LM, Birx DL, VanCott TC.
    J Virol; 1998 Dec 30; 72(12):9656-67. PubMed ID: 9811699
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.